CFDE Data Portal | Search DPH5-DT

	Label	Description
	DPH5-DT Gene (Entity type)	ENSG00000233184 - DPH5 divergent transcript
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE207871 NPC knockdown S18 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 7 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE129542 BAT1 knockdown RNA Small Interfering 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 0 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193993 SSTR2 knockout 5 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS

DPH5-DT

ENSG00000233184 - DPH5 divergent transcript

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn

A Gene Set from LINCS

GSE207871 NPC knockdown S18 1 v 0 human up

A Gene Set from LINCS

GSE216043 cisplatin 11 v 2 human dn

A Gene Set from LINCS

GSE216043 cisplatin 7 v 0 human dn

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

GSE129542 BAT1 knockdown RNA Small Interfering 0 v 2 human up

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 0 v 7 human up

A Gene Set from LINCS

GSE193993 SSTR2 knockout 5 v 3 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.